Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis

References

• International Agency for Research on Cancer. Cancer fact sheets: Lung cancer. Globocan [Internet]. Lyon (France): IARC. 2018 [cited 2018 Sep 20]. Available from: http://gco.iarc.fr/today/fact-sheets-cancers
   Google Scholar
• Bonomi PD. Implications of key trials in advanced nonsmall cell lung cancer. Cancer. 2010;116(5):1155–1164.
   PubMed Web of Science ®Google Scholar
• Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27 (5):v1–v27.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology NSCLC (version 6) [Internet]. Plymouth (PA): NCCN. 2018 [cited 2018 Sep 14]. Available from: https://www.nccn.org/
   Google Scholar
• Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011;17(17):5530–5537.
   PubMed Web of Science ®Google Scholar
• Russo A, Franchina T, Ricciardi GRR, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. Crit Rev Oncol Hematol. 2017;117:38–47.
   PubMed Web of Science ®Google Scholar
• Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.
   PubMed Web of Science ®Google Scholar
• Engelman J, Jänne P. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14(10):2895–2899.
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247.
   PubMed Web of Science ®Google Scholar
• Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–1061.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699.
   PubMed Web of Science ®Google Scholar
• Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–5140.
   PubMed Web of Science ®Google Scholar
• Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. JCO. 2017;35(12):1288–1296.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• De Marinis F, Cho BC, Kim DW, et al. ASTRIS: a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC). JCO. 2017;35(15):9036.
   Web of Science ®Google Scholar
• Wu Y, Cho BC, Zhou Q, et al. ASTRIS: a real world treatment study of osimertinib in patients with EGFR-T790M-positive NSCLC [Abstract MA02.03] [Internet]. Paper presented at the International Association for the Study of Lung Cancer (IASCL), 19th World Conference on Lung Cancer; 2018 September 23–26; Toronto, Canada. [cited 2018 Oct 26]. Available from: https://wclc2018.iaslc.org/wp-content/uploads/2018/09/WCLC2018-Abstract-Book_vF-LR-REV-SEPT-25-2018.pdf
   Google Scholar
• Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small- cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–1652.
   PubMed Web of Science ®Google Scholar
• Jenkins S, Chih-Hsin Yang J, Jänne PA, et al. EGFR mutation analysis for prospective patient selection in two phase II registration studies of osimertinib. J Thorac Oncol. 2017;12(8):1247–1256.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(33):3290–3297.
   Web of Science ®Google Scholar
• Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3375–3382.
   PubMed Web of Science ®Google Scholar
• Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015;90(3):509–515.
   PubMed Web of Science ®Google Scholar
• Passiglia F, Rizzo S, Di Maio M, et al. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Sci Rep. 2018;8(1):13379.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol. 2018;13(9):1248–1268.
   PubMed Web of Science ®Google Scholar
• Akamatsu H, Katakami N, Okamoto I, et al. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci. 2018;109(6):1930–1938.
   PubMed Web of Science ®Google Scholar
• Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36(26):2702–2709.
   PubMed Web of Science ®Google Scholar